Skip to main content
MCRB
NASDAQ Life Sciences

Seres Therapeutics Reports Q1 Loss, Short Cash Runway, Awaits Key Clinical Data Amid Funding Search

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$7.84
Mkt Cap
$74.071M
52W Low
$6.53
52W High
$29.98
52W Position info
20% above low
Off High info
74% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

MCRB sits 20% above its 52-week low of $6.53.

Summary

Seres Therapeutics reported a Q1 net loss and a short cash runway through Q3 2026, intensifying its search for funding, while awaiting key clinical data for its SER-155 program.


Key Events · Financing and Capital Events · MCRB

  • Q1 Financial Results Show Net Loss

    The company reported a net loss of $19.9 million for the first quarter of 2026, a significant decline from a net income of $32.7 million in the same period of 2025, largely due to the absence of a $50 million payment from Nestlé.

  • Shortened Cash Runway

    As of March 31, 2026, Seres had $29.8 million in cash and cash equivalents and expects to fund operations only through the third quarter of 2026, highlighting an urgent need for additional capital.

  • Key Clinical Data Expected Soon

    A clinical readout from an investigator-sponsored study evaluating SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC) is anticipated in the coming weeks, representing a potential near-term catalyst.

  • Funding Sought for SER-155 Phase 2

    The SER-155 program for the prevention of bloodstream infections in allo-HSCT patients is Phase 2 ready, but the company is actively seeking funding to commence the study.


Analysis · MCRB · Life Sciences

Seres Therapeutics reported a net loss of $19.9 million for Q1 2026, a significant reversal from the prior year's net income, primarily due to the absence of a $50 million payment from Nestlé. The company's cash and cash equivalents stood at $29.8 million as of March 31, 2026, with an anticipated cash runway only through the third quarter of 2026. This short runway, following a previous going concern warning, underscores the urgent need for additional capital and partnerships to advance its pipeline. While the financial situation is challenging, the company anticipates a clinical readout from an investigator-sponsored SER-155 study in immune checkpoint inhibitor-related enterocolitis in the coming weeks, which could serve as a critical near-term catalyst.

How filings like this one have moved

In the 30 days to Nov 15, 2026, 48.2% of the 1980 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MCRB was trading at $7.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $74.1M. The 52-week trading range was $6.53 to $29.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MCRB - Latest Insights

MCRB
Nov 04, 2026, 10:00 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.87
Real-time Price: $1.40 info
Change: -$0.470 (-25%) info
Market Cap: $14.273M info
MCRB
Nov 04, 2026, 7:05 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.79
Real-time Price: $1.40 info
Change: -$0.390 (-22%) info
Market Cap: $14.273M info
MCRB
Nov 04, 2026, 7:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.74
Real-time Price: $1.40 info
Change: -$0.335 (-19%) info
Market Cap: $14.273M info
MCRB
Oct 26, 2026, 4:30 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.98
Real-time Price: $1.40 info
Change: -$0.580 (-29%) info
Market Cap: $14.273M info
MCRB
Aug 05, 2026, 10:30 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $5.04
Real-time Price: $1.40 info
Change: -$3.64 (-72%) info
Market Cap: $14.273M info